Research Paper Volume 13, Issue 16 pp 20661—20683
METTL21B is a prognostic biomarker and potential therapeutic target in low-grade gliomas
Figure 2. The association between METTL21B expression and clinical features. (A) age; (B) gender; (C) race; (D) WHO grade. *P<0.05; **P<0.01.